detention and possible refusal at the port. FDA requests the following information from each processor seeking to be included on the lists:

1. Business name and address;
2. Name and telephone number of person designated as business contact;
3. Lists of products presently being shipped to the EC and those intended to be shipped in the next 6 months;
4. Name and address of manufacturing plants for each product; and
5. Names and affiliations of any Federal, State, or local governmental agencies that inspect the plant, government-assigned plant identifier such as plant number, and last date of inspection.

In the **Federal Register** of June 21, 2007 (72 FR 34256), FDA published a 60-day notice requesting public comment on the information collection provisions. No comments were received.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN[1]

Products	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Shell Eggs	10	1	10	.25	3
Dairy	120	1	120	.25	30
Game Meat and Meat Products	5	1	5	.25	1
Animal Casings	5	1	5	.25	1
Gelatin	3	1	3	.25	1
Collagen	3	1	3	.25	1
Total					37

[1]There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA bases its estimate on the responses received over the past 3 years. We estimate that the annual reporting burden would be approximately 37 hours. The time to respond to the questions should take approximately 15 minutes using any of the technologies available to transmit the information. All of the information asked for should be readily available. No record retention is required. In previous years, FDA estimated that the agency's communication with trade associations and states resulted in a reporting burden of 520 hours. FDA no longer receives information from trade associations and states under this program. Accordingly, the proposed annual burden for this information collection has been reduced by 520 hours. Therefore, the proposed annual burden for this information collection is 37 hours.

Dated: September 6, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7–18033 Filed 9–11–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Cardiovascular and Renal Drugs Advisory Committee. This meeting was announced in the **Federal Register** of August 14, 2007 (72 FR 45435). The amendment is being made to reflect a change in the *Date and Time* and *Agenda* portions of the meeting. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Cathy A. Miller, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5630 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, e-mail: *Cathy.Miller1@fda.hhs.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512533. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 14, 2007, FDA announced that a meeting of the Cardiovascular and Renal Drugs Advisory Committee would be held on October 16 and 17, 2007.

On page 45435, in the second column, the *Date and Time* portion of the document is amended to read as follows:

Date and Time: The meeting will be held on October 16, 2007, from 8 a.m. to 5 p.m.

On page 45435, in the third column, the *Agenda* portion of the document is amended to read as follows:

Agenda: On October 16, 2007, the committee will discuss regulatory considerations for extending the use of phosphate binders from the dialysis population (where they are approved) to the pre-dialysis population (where no products are approved). The committee will hear presentations on this topic from Shire Development, Genzyme Corp., and Fresenius Medical Care.

Dated: September 5, 2007.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E7–18031 Filed 9–11–07; 8:45 am]

BILLING CODE 4160–01–S